Foods & Flavours

Amino GmbH Announces Plans to Double Production Capacity, Expand Market in U.S.

12th February 2020
Frellstedt, Germany – Amino GmbH, which produces high-quality pharmaceutical-grade amino acids for pharmaceutical, medical and clinical dietetic nutrition applications, today announced plans to double production capacity by building a new facility at its Frellstedt, Germany location. Amino is investing approximately $35 million to meet the growing demand of current customers and to increase supply and availability for the worldwide pharmaceutical and nutritional market, with a specific focus on the American markets. Construction will begin by March 31 and the new facility will begin operation in 2021.


“We are expanding because we believe in ourselves and we want to offer our services to a broader audience,” said Dr. Lutz Thomas, Managing Director.  “We will be an even stronger source for companies in the high-end pharmaceutical grade amino acid market.” 


Dr. Thomas said that by building the new facility, Amino will increase production by about 1200 metric tons across all product lines, the complete range of pharmaceutical grade amino acids. Serving Europe, Asia and the Americas, Amino specializes in amino acids for: infusions and injections; active pharmaceutical ingredients for oral applications; pharma-intermediates; pharmaceutical production in cell cultures, and medical nutrition and infant formula.


Amino has registered rapid and consistent annual growth for more than 10 years by adding value beyond the amino acid and helping customers solve their production problems.  To that end, Amino has invested heavily in R&D, creating its AminoVation platform to expand its line of products and services and respond even faster and more specifically to customers’ needs.
“We are developing the next generation of products for the next generation of employees and managers,” said Dr. Thomas. “Building on our current portfolio we are developing amino acid derivatives and other APIs and nutrients.”
Current growth is exhausting Amino’s production capacity, Dr. Thomas added, and the company now needs to think bigger and beyond its European base.


“The U.S. is a good cultural fit, and we plan to expand our marketing there,” said Kai-Phillipp Thomas, V.P. of Sales & Marketing.  “The new facility enables Amino to supply new customers, particularly pharmaceutical companies in the U.S., while also meeting increasing demand from our existing customer base.”   
Amino pharmaceutical amino acids meet the highest quality standards and the requirements of such international pharmacopoeias as:


  • United States Pharmacopoeia (USP)
  • European Pharmacopoeia (Ph. Eur.)
Amino has passed US Food & Drug Administration inspections and holds several US-Drug Master Files.